These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 36639192

  • 1. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R.
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
    [Abstract] [Full Text] [Related]

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 3. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF, Abreu G, Furie RA, Golder V, Tummala R.
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
    Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, Lawrence Ford T, Gupta R, Hiepe F, Santiago M, Brohawn PZ, Berglind A, Tummala R, TULIP-1 study investigators.
    Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
    [Abstract] [Full Text] [Related]

  • 6. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
    Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1526-1534. PubMed ID: 36018235
    [Abstract] [Full Text] [Related]

  • 7. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
    Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R.
    Arthritis Rheumatol; 2021 Nov 03; 73(11):2059-2068. PubMed ID: 33913260
    [Abstract] [Full Text] [Related]

  • 8. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V, O'Quinn S, Furie RA, Morand EF, Kalunian KC, Schwetje EG, Abreu G, Tummala R.
    Lancet Rheumatol; 2022 Mar 03; 4(3):e198-e207. PubMed ID: 38288936
    [Abstract] [Full Text] [Related]

  • 9. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R.
    Ann Rheum Dis; 2022 Jul 03; 81(7):951-961. PubMed ID: 35338035
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Hayashi N, Abreu G, Tummala R, Morand EF, Takeuchi T.
    Mod Rheumatol; 2023 Jan 03; 33(1):134-144. PubMed ID: 35134970
    [Abstract] [Full Text] [Related]

  • 11. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators.
    Arthritis Rheumatol; 2017 Feb 03; 69(2):376-386. PubMed ID: 28130918
    [Abstract] [Full Text] [Related]

  • 12. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
    Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R.
    Ann Rheum Dis; 2018 May 03; 77(5):706-713. PubMed ID: 29420200
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, Pineda L, Tummala R.
    Lancet Rheumatol; 2022 Apr 03; 4(4):e282-e292. PubMed ID: 38288923
    [Abstract] [Full Text] [Related]

  • 14. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
    Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R.
    Lupus; 2021 Jul 03; 30(8):1254-1263. PubMed ID: 33977796
    [Abstract] [Full Text] [Related]

  • 15. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
    Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF.
    Rheumatology (Oxford); 2022 May 05; 61(5):1900-1910. PubMed ID: 34528084
    [Abstract] [Full Text] [Related]

  • 16. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R, TULIP-2 Trial Investigators.
    N Engl J Med; 2020 Jan 16; 382(3):211-221. PubMed ID: 31851795
    [Abstract] [Full Text] [Related]

  • 17. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, Morand EF, Furie RA.
    J Clin Pharmacol; 2022 Sep 16; 62(9):1094-1105. PubMed ID: 35352835
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
    Burge DJ, Werth VP, Boackle SA, Posada J.
    Lupus Sci Med; 2024 Feb 07; 11(1):. PubMed ID: 38325898
    [Abstract] [Full Text] [Related]

  • 19. Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials.
    Stull D, O'Quinn S, Williams B, Bean S, Schwetje E, Abreu G, Tummala R.
    Rheumatology (Oxford); 2022 Nov 28; 61(12):4731-4740. PubMed ID: 35274691
    [Abstract] [Full Text] [Related]

  • 20. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y, Tummala R.
    Mod Rheumatol; 2021 Jan 28; 31(1):1-12. PubMed ID: 32814461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.